Harpreet Singh, Chief Medical Officer at Precision For Medicine, shared a post on LinkedIn:
“Earlier this month, I had the pleasure of speaking with Dr. Cesar Perez, M.D., Director of the Drug Development Unit at the Sarah Cannon Research Institute at Florida Cancer Specialists and Research Institute, to discuss the phase 1/2 data on CRB-701, a next-generation Nectin-4–targeting ADC presented at ESMO 2025.
CRB-701 is designed to minimize dose-limiting toxicities commonly seen with MMAE-based ADCs, delivering what Dr. Perez described the precision and promise ADCs are known for. The early data are encouraging, demonstrating robust response rates, durable disease control across tumor types, and a manageable safety profile with fewer ocular and neuropathy-related events.
It’s exciting to see an ADC candidate showing promising early data across this range of indications, including head and neck squamous cell carcinoma and cervical cancer. We look forward to seeing how this program evolves through dose optimization and maturation of data.
Watch the full conversation here to learn more about this promising molecule and what it could mean for the next generation of ADC development.”
Proceed to the video attached to the post.
More posts featuring Harpreet Singh.